Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

GPhC to consult on new registration route for international pharmacists in 2025

GPhC to consult on new registration route for international pharmacists in 2025
"Our Council has listened and decided to propose one single route for all non-EEA/EFTA internationally-qualified pharmacists," Duncan Rudkin, Chief Executive of the GPhC, announced.

In response to stakeholder feedback, the General Pharmaceutical Council (GPhC) is developing a streamlined, single route to registration that will replace the current multiple-pathway system for overseas pharmacists wishing to practice in Great Britain.

This revised approach will include updated standards for the education and training of internationally qualified pharmacists, with all applicants still required to pass a registration assessment.


The GPhC's Council intends to streamline the registration pathway, reducing the two-year process to one-year process.

This new pathway will encompass both university study and in-practice training.

Historically, pharmacists qualified within the European Economic Area (EEA) or European Free Trade Association (EFTA) have been eligible for qualification recognition in Great Britain.

While this recognition has been extended until September 2028, the future requirement for EEA-qualified pharmacists to undergo the new registration route remains contingent on forthcoming government decisions.

Initially, the GPhC had explored the development of three distinct registration routes for internationally-qualified pharmacists, "however decided to change this proposed approach after considering feedback from stakeholders."

The extensive feedback highlighted concerns regarding fairness and inclusivity in the original proposal, leading to a reassessment and the decision to pursue a unified, one-year pathway.

Duncan Rudkin, Chief Executive of the GPhC, emphasised the Council's commitment to equality, diversity, and inclusivity.

"While stakeholders generally welcomed the reduction in time and cost, concerns were raised about fairness.

Additionally, Rudkin stated that the GPhC would also be focusing their efforts "at this point on taking forward the one-year programme, because a significant proportion of overseas applicants are applying from countries such as India, Pakistan and Nigeria, who would need to complete a one-year programme.

“We also intend that shortening the course from two years to one year, once implemented, will significantly reduce the burden for internationally-qualified pharmacists and help to increase the pharmacist workforce in the long-term"

Looking ahead, the GPhC will further refine the details of this proposed approach, alongside drafting updated standards for the education and training of internationally-qualified pharmacists.

A public consultation on these proposals is slated for 2025, with the changes to the Overseas Pharmacists Assessment Programme (OSPAP) expected no earlier than September 2026.

In addition to this, the GPhC is considering a similar review for internationally-qualified pharmacy technicians, focusing on a shorter registration route based on prior learning.

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.

Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.

iStock

Locums should stand up for their interests, say 'no' to unfair terms: PDA

The Pharmacists' Defence Association (PDA) has advised locum pharmacists to be vigilant about their interests and negotiate directly with their businesses, avoid working with digital platforms driven by algorithms, and be aware of regressive contract terms.

The not-for-profit organisation issued such an advisory following its survey of 1,300 UK locum pharmacists, which showed that they work in a difficult environment and that most are dissatisfied with their jobs.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less